Intérêt clinique du calcul des pentes de variation du CA 125 pour la surveillance biologique des tumeurs épithéliales ovariennes
Tài liệu tham khảo
Bast, 1983, A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer, N Engl J Med, 309, 883, 10.1056/NEJM198310133091503
Brioschi, 1987, Serum CA 125 in epithelial ovarian cancer. A longitudinal study, Br J Obstet Gynecol, 94, 196, 10.1111/j.1471-0528.1987.tb02353.x
Canney, 1984, Ovarian cancer antigen CA 125: a prospective clinical assessment of its role as a tumour marker, Br J Cancer, 50, 765, 10.1038/bjc.1984.254
Cruickshank, 1991, The potential value of CA 125 as a tumor marker in small volume, non-evaluable epithelial ovarian cancer, Int J Biol Markers, 6, 247, 10.1177/172460089100600406
Folk, 1995, Monitoring Cancer Antigen 125 levels in induction chemotherapy for epithelial ovarian carcinoma and predicting outcome of second-look procedure, Gynecol Oncol, 57, 178, 10.1006/gyno.1995.1121
Gadducci, 1996, Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses, Gynecol Oncol, 60, 197, 10.1006/gyno.1996.0025
Gadducci, 1996, The relationship between postoperative decline of serum CA 125 levels and size of residual disease after initial surgery in patients with advanced ovarian cancer: a CTF study, Gynecol Oncol, 63, 234, 10.1006/gyno.1996.0312
Gallion, 1992, The prognostic implications of low serum CA 125 levies prior to the second look operation for stage III and IV Epithelial Ovarian cancer, Gynecologic Oncology, 46, 29, 10.1016/0090-8258(92)90190-T
Hawkins, 1989, The clinical correlates of serum CA 125 in 169 patients with epithelial ovarian carcinoma, Br J Cancer, 60, 634, 10.1038/bjc.1989.329
Hogdall, 1996, Use of tetranectin, CA 125 and CASA to predict residual tumor and survival at second-look-and third-look operations for ovarian cancer, Acta Oncol, 35, 63, 10.3109/02841869609098481
Medl, 1995, Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in patients with epithelial ovarian cancer, Anticancer Res, 15, 2727
Riedinger, 1996, Prognostic value of CA 125 initial half-life measured during first-line chemothérapy in 62 patients with epithelial ovarian cancer stage III or IV, Bull Cancer, 83, 654
Riedinger, 1997, Clinical value of the estimation of growth kinetics of primary ovarian cancer recurrences by CA 125 doubling time, Bull Cancer, 84, 855
Rosman, 1994, Prognostic indicators for poor risk epithelial ovarian carcinoma, Cancer, 74, 4, 10.1002/1097-0142(19940815)74:4<1323::AID-CNCR2820740423>3.0.CO;2-5
Rosman, 1994, Prognostic indicators for poor risk epithelial ovarian carcinoma, Cancer, 74, 1323, 10.1002/1097-0142(19940815)74:4<1323::AID-CNCR2820740423>3.0.CO;2-5
Talbot, 1989, Temporary elevation of CA 125 aftet abdominal surgical treatment for benign disease and cancer, Sur Gynecol Obstet, 168, 407
Toftager-Larsen, 1992, Ca 125, placental alkaline phosphatase and tissue polypeptide antigen as preoperative serum markers in ovarian carcinoma, Gynecol Obstet Invest, 33, 177, 10.1159/000294876
Van der Zee, 1990, The effect of abdominal surgery on the serum concentration of the tumour-associated antigen CA 125, BrJ Obstet Gynaecol, 97, 934, 10.1111/j.1471-0528.1990.tb02450.x
Vergote, 1987, Evaluation of serum CA 125 levels in the monitoring of ovarian cancer, Am J Obstet Gynecol, 157, 88, 10.1016/S0002-9378(87)80352-6
Yedema, 1993, CA 125 half-life in ovarian cancer: a multivariate survival analysis, Br J Cancer, 67, 1361, 10.1038/bjc.1993.252
Yedema, 1993, CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery, Eur j Cancer, 29A, 966, 10.1016/S0959-8049(05)80203-5